Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus PYOCIDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus PYOCIDIN.
COR-OTICIN vs PYOCIDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Pyocidin is a bactericidal antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
1-2 drops in each affected ear twice daily for 7 days.
5 mg/kg intramuscular or subcutaneous every 24 hours. Max dose 300 mg per injection.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life is 2-3 hours in patients with normal renal function; extends to 12-18 hours in severe renal impairment (CrCl <30 mL/min).
Renal (60-80% unchanged), fecal/biliary (5-10%)
Primarily renal excretion of unchanged drug (60-70%), with 20-30% biliary excretion and minor fecal elimination (<10%).
Category C
Category C
Topical Corticosteroid + Antibiotic
Antibiotic